These findings support the notion that CaMKK2 controls metabolic flexibility in the liver and are further supported by our observations here that STO-609S treatment in two mouse models of NAFLD promotes reprogramming of glycolytic and fatty acid oxidation programs to reverse hepatic steatosis. Here, CAMKK2 is linked to metabolic dysfunction-associated steatotic liver disease.